E Fund Management Co., Ltd. Humanigen, Inc Transaction History

E Fund Management Co., Ltd.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$3.66 - $8.22 $91,697 - $205,943	-25,054 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$5.93 - $17.83 $97,406 - $292,875	16,426 Added 190.38%	25,054 $149,000
Q1 2021 May 12, 2021	BUY	$12.91 - $23.83 $111,387 - $205,605	8,628 New	8,628 $164,000

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on E Fund Management Co., Ltd. with notifications on news.